Research

Blog Posts

• VAIL SUCCESSFULLY COMPLETED (OVERSUBSCRIBED) SERIES B FUNDING

  At the end of August 2021, Vail Scientific successfully closed an oversubscribed Series B round. The round was led by Vail Investor Group and its leader and Vail board member, Mike Nathan. Nathan shares, “I, along with the Vail Investor Group, have a real passion for transformative innovation. Sepsis diagnosis is a space that needs disruption. We are excited about the potential applications of this science.”

  The round was followed by other engaged investors including the investor from our Series A Round. Our investors are committed to scientific advancement that improves the lives of others and understand the perpetual challenge that the proper detection of Sepsis poses to patients and the medical community at large.

  Proceeds are being used to fund a proof-of-concept study to validate our initial pilot study. This is being run through our clinical partner, HealthPartners. Findings from this study will allow us to build a proprietary version of the diagnostic device.

  CEO and co-founder Tom Burke says, “Vail Scientific is extremely excited to have a group of impassioned investors who look to bring about disruptive positive change to the challenge of Sepsis screening and treatment.”

  As a team of inventors, we are ready to begin the next phase of our work.

• VAIL LAUNCHES NO-SEPSIS TRIAL

  Our work continues because patients with sepsis cannot wait.

  Vail Scientific is pleased to announce the official start of its proof-of-concept NO-SEPSIS clinical study with HealthPartners. It will be conducted at HealthPartners facilities in the Minneapolis-St. Paul area. Thanks to our previous pilot study we were able to identify two statistically significant measurements. These measurements included the ability to distinguish between healthy volunteers and ER patients suspected of having sepsis as well as the ability to identify within an ER sepsis protocol patient population which patients had sepsis and which did not. This initial pilot study was completed by Principal Investigator Greg Beilman, MD at the University of Minnesota.

  The proof-of-concept NO-SEPSIS study will be critical to the development of Vail’s technology. It will enable us to validate results within larger ER patient and healthy volunteer populations. This gets us a step closer toward bringing our technology to market, which is vital for future patients and important to the Vail team. Current sepsis patient screening tests are deficient, and Vail’s technology will set a new standard of care in the early detection of sepsis.

  Michael Zwank, MD and Kendal Farrar, MD, FACEP will be the Principal Investigators of the NO-SEPSIS study.

  Michael Zwank, MD is an emergency medicine physician at Regions Hospital and an Associate Professor at the University of Minnesota Medical School. He is the Ultrasound Director for the Regions Hospital Emergency Department. He has participated in a wide range of research projects involved in diagnostic imaging, neurologic emergencies, resource utilization and patient flow. He states, “I am excited to be part of the team examining this novel technology to revolutionize the diagnosis of sepsis.” Kendal Farrar, MD, FACEP is an emergency medicine physician at Methodist Hospital in St. Louis Park, Minnesota, where she is the Associate Director of Quality Improvement. She has led several clinical trials with a focus on Quality Improvement, such as early recognition of hypertension, decreasing opioid prescribing in the ED, and the use of convalescent plasma in COVID patients. She says, “I look forward to the potential for this technology to rapidly and accurately detect septic patients upon their arrival to the emergency department.”